Ratings Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Stocks

6990

CNE1000062J1

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:30 2026-06-11 EDT 5-day change 1st Jan Change
394.40 HKD -1.74% Intraday chart for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. -1.05% +0.56%

Ratings Surperformance

Trader
Investor
-
Global
-
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Rating Financials

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SectorHong Kong

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

-

Gearing

Leverage

-

Capital Intensity

-

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SectorHong Kong

Global Valuation

-

Enterprise Value

-

EV/Revenue

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SectorHong Kong

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SectorHong Kong

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SectorHong Kong

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
11.94B -
AA
- -
54.82B
A
43.27B
AAA
21.79B - - - -
19.92B -
A
- -
15.67B
AAA
15.26B
A
13.22B
BB
11.58B
AA
10.13B - - - -
Average 21.76B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. 6990 Stock
  4. Ratings Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!